Brokerages Set Cellebrite DI Ltd. (NASDAQ:CLBT) PT at $21.40

Cellebrite DI Ltd. (NASDAQ:CLBT) has earned an average recommendation of “Moderate Buy” from the six ratings firms that are currently covering the company, MarketBeat Ratings reports. One analyst has rated the stock with a hold recommendation and five have issued a buy recommendation on the company. The average 12 month price objective among analysts that have covered the stock in the last year is $21.40.

Several brokerages recently issued reports on CLBT. Needham & Company LLC decreased their price target on shares of Cellebrite DI from $18.00 to $15.00 and set a “buy” rating on the stock in a report on Friday, May 15th. DA Davidson began coverage on shares of Cellebrite DI in a research note on Wednesday, May 27th. They issued a “buy” rating and a $20.00 price objective for the company. Finally, Weiss Ratings upgraded shares of Cellebrite DI from a “sell (d+)” rating to a “hold (c-)” rating in a research report on Monday, May 18th.

Insider Activity

In related news, CFO David Barter sold 41,734 shares of the business’s stock in a transaction on Wednesday, July 8th. The stock was sold at an average price of $16.38, for a total transaction of $683,602.92. Following the sale, the chief financial officer owned 334,219 shares in the company, valued at $5,474,507.22. The trade was a 11.10% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, CEO Thomas E. Hogan sold 103,188 shares of the company’s stock in a transaction dated Thursday, July 2nd. The stock was sold at an average price of $15.76, for a total value of $1,626,242.88. Following the completion of the transaction, the chief executive officer directly owned 590,777 shares of the company’s stock, valued at approximately $9,310,645.52. The trade was a 14.87% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last ninety days, insiders sold 158,191 shares of company stock worth $2,479,438. Insiders own 5.70% of the company’s stock.

Institutional Trading of Cellebrite DI

A number of hedge funds have recently made changes to their positions in CLBT. Towarzystwo Funduszy Inwestycyjnych PZU SA grew its holdings in shares of Cellebrite DI by 81.0% during the fourth quarter. Towarzystwo Funduszy Inwestycyjnych PZU SA now owns 1,900 shares of the company’s stock worth $34,000 after purchasing an additional 850 shares during the last quarter. Advisory Services Network LLC bought a new position in Cellebrite DI in the 3rd quarter valued at approximately $40,000. CWM LLC boosted its position in Cellebrite DI by 57.0% during the 4th quarter. CWM LLC now owns 2,449 shares of the company’s stock worth $44,000 after buying an additional 889 shares during the period. Elevation Wealth Partners LLC acquired a new stake in Cellebrite DI during the 2nd quarter worth approximately $44,000. Finally, First Horizon Corp grew its holdings in Cellebrite DI by 421.8% during the 4th quarter. First Horizon Corp now owns 2,891 shares of the company’s stock worth $52,000 after acquiring an additional 2,337 shares during the last quarter. 45.88% of the stock is owned by institutional investors and hedge funds.

Cellebrite DI Trading Up 0.3%

Shares of NASDAQ CLBT opened at $16.18 on Friday. The company has a market cap of $4.04 billion, a price-to-earnings ratio of 57.79, a PEG ratio of 2.00 and a beta of 1.17. Cellebrite DI has a 12 month low of $11.02 and a 12 month high of $19.98. The stock has a 50-day moving average price of $13.88 and a two-hundred day moving average price of $14.46.

About Cellebrite DI

Cellebrite DI is a global provider of digital intelligence and forensics solutions that enable law enforcement agencies, government bodies and enterprises to extract, analyze and act on data from mobile devices, cloud services and digital sources. The company’s technology is designed to accelerate investigations, support evidence-based decision-making and enhance security operations by delivering actionable intelligence in a secure, scalable platform.

The company’s flagship offerings include the Universal Forensic Extraction Device (UFED) series for data acquisition and decoding, Physical Analyzer for advanced data parsing and visualization, and Pathfinder for case-driven investigation workflows.